Downregulation of miR‑186 promotes the proliferation and drug resistance of glioblastoma cells by targeting Twist1

  • Authors:
    • Yifeng Xiong
    • Rensheng Chen
    • Lizhen Wang
    • Shanshan Wang
    • Yi Tu
    • Lei Zhu
    • Chunliang Wang
  • View Affiliations

  • Published online on: April 30, 2019     https://doi.org/10.3892/mmr.2019.10207
  • Pages: 5301-5308
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Temozolomide (TMZ) is widely used as a chemotherapeutic agent in the treatment of glioma; however, the development of drug resistance remains a major obstacle in the effective treatment of glioblastoma. Increasing evidence has indicated that microRNAs (miRs) are involved in the drug resistance of glioma; however, the role of miR‑186‑5p in the TMZ resistance of glioblastoma remains unknown. In the present study, the role of miR‑186‑5p in the resistance of glioblastoma to TMZ was investigated. mRNA and protein expression levels were detected via reverse transcription‑quantitative PCR and western blot analysis, respectively. It was determined that miR‑186‑5p was significantly downregulated in glioblastoma tissues and cell lines. Additionally, the expression of miR‑186‑5p was decreased, whereas that of Twist1 was upregulated during the development of drug resistance in glioma cells. The introduction of miR‑186 into glioblastoma cells via transfection decreased the proliferation and TMZ resistance of glioblastoma cells, as determined via 5‑ethynyl‑2'‑deoxyuridine and Cell Counting Kit‑8 assays, whereas the inhibition of miR‑186‑5p induced opposing effects. Furthermore, luciferase reporter and expression rescue assays revealed that miR‑186‑5p bound to the 3'‑untranslated region of Twist‑related protein 1 (Twist1). In conclusion, the present study demonstrated that downregulation of miR‑186‑5p may contribute to the proliferation and drug resistance of glioblastoma cells via the regulation of Twist1 expression. These results suggested that miR‑186‑5p may be a novel therapeutic target in the treatment of glioblastoma.
View Figures
View References

Related Articles

Journal Cover

June 2019
Volume 19 Issue 6

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Xiong, Y., Chen, R., Wang, L., Wang, S., Tu, Y., Zhu, L., & Wang, C. (2019). Downregulation of miR‑186 promotes the proliferation and drug resistance of glioblastoma cells by targeting Twist1. Molecular Medicine Reports, 19, 5301-5308. https://doi.org/10.3892/mmr.2019.10207
MLA
Xiong, Y., Chen, R., Wang, L., Wang, S., Tu, Y., Zhu, L., Wang, C."Downregulation of miR‑186 promotes the proliferation and drug resistance of glioblastoma cells by targeting Twist1". Molecular Medicine Reports 19.6 (2019): 5301-5308.
Chicago
Xiong, Y., Chen, R., Wang, L., Wang, S., Tu, Y., Zhu, L., Wang, C."Downregulation of miR‑186 promotes the proliferation and drug resistance of glioblastoma cells by targeting Twist1". Molecular Medicine Reports 19, no. 6 (2019): 5301-5308. https://doi.org/10.3892/mmr.2019.10207